APLI:CC News and Press, Appili Therapeutics Inc. From 06/25/25

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTC...

Pedro Resources Ltd (VBN:CNX) is expected to report for quarter end 2025-03-31 BlackBerry Limited (BB:CA) is expected to report $-0.01 for Q1 2026 STLLR Gold Inc. (STLR:CA) is expected to report for Q1 2025 Appili Therapeutics Inc. (APLI:CA) is expected to report for quarter end 2025-...

Appili Therapeutics Inc. (APLI:CA) is expected to report for quarter end 2025-03-31

2025-06-09 09:09:56 ET Aditxt (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors as the company advances toward commercialization and sharpens its focus on women’s health. Pelletier brings more than 30 years of globa...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceuti...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceuti...

2025-05-02 09:40:00 ET Aditxt (NASDAQ: ADTX) announced that Chief Innovation Officer Dr. Shahrokh Shabahang and Adimune Co-CEO Dr. Friedrich Kapp will participate in today’s Aditxt Weekly Update to discuss recent progress on ADI-100 , the lead therapeutic candidate of its wholly ...

HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a p...

New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book HALIFAX, Nova...

2025-04-17 10:15:00 ET Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100 , the lead therapeutic candidate from Aditxt’s ...